Michel Sadelain and Prasad Adusumilli
Finding
By Julie Grisham, MS, Science Writer/Editor  |  Wednesday, November 19, 2014

A study in mouse models suggests how modified T cells may be used to treat tumors in the area just outside the lungs.

(From left) MSK investigators Michael Berger, José Baselga, and Maurizio Scaltriti, and graduate student Pau Castel.
Finding
By Julie Grisham, MS, Science Writer/Editor  |  Monday, November 17, 2014

A study of one patient’s disease has clarified why tumors stop responding to a class of experimental drugs called PI3K inhibitors.

Gregory Riely
In the Clinic
By Jim Stallard, MA, Writer/Editor  |  Wednesday, November 12, 2014

MSK lung cancer patients benefit from a powerful genomic test that looks for mutations in 341 genes to help determine the best treatment.

Q&A
By Esther Napolitano, BS, Science Writer/Editor  |  Monday, October 20, 2014

Medical oncologist Paul Sabbatini demystifies common misconceptions surrounding clinical trials.

DNA wrapped around histones
Decoder
By Julie Grisham, MS, Science Writer/Editor  |  Tuesday, October 14, 2014

Physician-scientist Omar Abdel-Wahab explains epigenetics, a growing field based on the study of genetic changes that are not part of the DNA code, and how it relates to cancer.

Pictured: Paul Sabbatini
Q&A
By Esther Napolitano, BS, Science Writer/Editor  |  Wednesday, September 24, 2014

Medical oncologist Paul Sabbatini sheds light on how phase I clinical trials are conducted at Memorial Sloan Kettering and how to determine whether patients may be eligible for one.

Pictured: Gabriela Chiosis
Finding
By Celia Gittelson, BA  |  Thursday, July 17, 2014

A small molecule discovered at MSK called PU-H71 blocks the growth of cancer cells and enables doctors to image tumors.

Pictured: Peter Allen
In the Clinic
By Jim Stallard, MA, Writer/Editor  |  Wednesday, June 18, 2014

A new drug could make pancreatic surgery safer by reducing the risk of a grave complication.

Pictured: Jedd Wolchok
MSK at ASCO
By Media Staff  |  Wednesday, June 4, 2014

Our experts offer their perspective in major media outlets on recent research into drug- and cell-based immunotherapies for cancer.

Pictured: Helen McArthur
In the Clinic
By Julie Grisham, MS, Science Writer/Editor  |  Tuesday, June 3, 2014

The treatment combines a technique called cryoablation, or freezing of the tumor, with an immunotherapy drug.

Pictured: David Solit
Profile
By Julie Grisham, MS, Science Writer/Editor  |  Tuesday, May 27, 2014

David Solit, Director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology, discusses how working with cancer patients drives him to develop more-effective, personalized cancer treatments.

Pictured: Mark Kris
Finding
By Julie Grisham, MS, Science Writer/Editor  |  Wednesday, May 21, 2014

A new study has found that driver mutations can be found in about two-thirds of lung adenocarcinomas, suggesting options for treatment with targeted therapies.

Pictured: José Baselga, Agnès Viale,  Michael Berger & David Solit
Announcement
By Eva Kiesler, PhD, Science Writer/Editor  |  Tuesday, May 20, 2014

With the creation of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering sets out to deliver on the promise of personalized medicine by creating better treatment options for all people with cancer.

pictured: Martin S. Tallman
Profile
By Maureen Salamon, BA, Freelance Writer  |  Monday, May 19, 2014

Leukemia Specialist Martin Tallman discusses how research has led to improvements in the treatment of leukemia and what challenges remain.

Pictured: William Tap
MSK at ASCO
By Media Staff  |  Thursday, May 15, 2014

New Memorial Sloan Kettering research demonstrates the powerful clinical benefit of giving patients a drug that targets the molecular abnormality driving the growth of a rare and debilitating joint disease.

Center News

Stay Informed

Get the latest information about cancer care and research every month.